Menu
Currency
GWAS Study

Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia.

Ruderfer DM, Fanous AH, Ripke S et al.

24280982 PubMed ID
GWAS Study Type
39202 Participants
43 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

RD
Ruderfer DM
FA
Fanous AH
RS
Ripke S
MA
McQuillin A
AR
Amdur RL
GP
Gejman PV
OM
O'Donovan MC
AO
Andreassen OA
DS
Djurovic S
HC
Hultman CM
KJ
Kelsoe JR
JS
Jamain S
LM
Landén M
LM
Leboyer M
NV
Nimgaonkar V
NJ
Nurnberger J
SJ
Smoller JW
CN
Craddock N
CA
Corvin A
SP
Sullivan PF
HP
Holmans P
SP
Sklar P
KK
Kendler KS
Chapter II

Abstract

Summary of the research findings

Bipolar disorder and schizophrenia are two often severe disorders with high heritabilities. Recent studies have demonstrated a large overlap of genetic risk loci between these disorders but diagnostic and molecular distinctions still remain. Here, we perform a combined genome-wide association study (GWAS) of 19 779 bipolar disorder (BP) and schizophrenia (SCZ) cases versus 19 423 controls, in addition to a direct comparison GWAS of 7129 SCZ cases versus 9252 BP cases. In our case-control analysis, we identify five previously identified regions reaching genome-wide significance (CACNA1C, IFI44L, MHC, TRANK1 and MAD1L1) and a novel locus near PIK3C2A. We create a polygenic risk score that is significantly different between BP and SCZ and show a significant correlation between a BP polygenic risk score and the clinical dimension of mania in SCZ patients. Our results indicate that first, combining diseases with similar genetic risk profiles improves power to detect shared risk loci and second, that future direct comparisons of BP and SCZ are likely to identify loci with significant differential effects. Identifying these loci should aid in the fundamental understanding of how these diseases differ biologically. These findings also indicate that combining clinical symptom dimensions and polygenic signatures could provide additional information that may someday be used clinically.

Up to 4,528 European ancestry schizophrenia cases, up to 4,841 schizophrenia cases, up to 7,362 European ancestry bipolar disorder cases, up to 3,048 bipolar disorder cases, up to 11,637 European ancestry controls, up to 7,786 controls

Chapter III

Study Statistics

Key metrics and study information

39202
Total Participants
GWAS
Study Type
No
Replicated
European, NR, European
Ancestry
Sweden, U.S., Germany, U.K., Republic of Ireland, Norway, Denmark, Bulgaria, Netherlands, Portugal, France, Australia, Canada
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.